argenx names Karen Massey as new CEO

argenx announced leadership changes and shareholder voting results from its Annual General Meeting.

Rhea-AI Filing Summary

argenx announced leadership changes and shareholder voting results from its Annual General Meeting. The Board of Directors appointed Karen Massey as Chief Executive Officer, succeeding co-founder Tim Van Hauwermeiren, who becomes Chairperson of the Board as a non-executive director.

Massey joined argenx in March 2023 as Chief Operating Officer and has been central to execution and long-term growth strategy, according to the Board. At the General Meeting, 90.9% of the company’s share capital was represented and all agenda items received the required majority of votes in favor.

Insights

Biopharma governance analyst

argenx executes planned CEO handover while maintaining founder influence as Board chair.

argenx is transitioning leadership by elevating Karen Massey from Chief Operating Officer to Chief Executive Officer, while co-founder Tim Van Hauwermeiren moves to Chairperson of the Board as a non-executive director. This preserves continuity at the board level while shifting day-to-day leadership.

Massey has been involved in argenx’s execution and long-term growth strategy since joining as COO in March 2023, suggesting familiarity with current operations and pipeline direction. The Board highlights her leadership focus on patients, company culture, and pipeline development, aligning her role with the existing strategic trajectory.

Shareholder support appears strong, with 90.9% of share capital represented at the Annual General Meeting and all agenda items receiving the required majority of votes. This broad backing indicates alignment between shareholders, the Board, and the new leadership structure at this stage.

Key Figures

AGM share capital represented: 90.9% CEO tenure start of Tim Van Hauwermeiren: 2008 Karen Massey joined argenx: March 2023 +1 more

4 metrics

AGM share capital represented 90.9% Share capital represented at the Annual General Meeting

CEO tenure start of Tim Van Hauwermeiren 2008 Year he began serving as Chief Executive Officer

Karen Massey joined argenx March 2023 Month and year she became Chief Operating Officer

AGM and leadership announcement date May 6, 2026 Date of Annual General Meeting and press release

Key Terms

Annual General Meeting, Chief Executive Officer, non-executive director, neonatal Fc receptor (FcRn) blocker, +1 more

5 terms

Annual General Meeting financial

"today announced the results of the Annual General Meeting of shareholders"

Chief Executive Officer financial

"appointment of Karen Massey as Chief Executive Officer"

A chief executive officer (CEO) is the top leader of a company, responsible for making major decisions, setting goals, and guiding the organization’s overall direction. Think of the CEO as the captain of a ship, steering it toward success. Investors pay close attention to the CEO because their leadership and strategy can significantly influence the company's performance and future growth.

non-executive director financial

"following his appointment as non-executive director to the Board of Directors"

A non-executive director is a member of a company’s board who does not work for the company day-to-day but provides independent oversight, strategic guidance and checks on management. For investors, they matter because they act like an impartial referee or outside advisor, helping ensure decisions protect shareholder interests, reduce risks of poor governance, and add credibility to financial reporting and long-term strategy.

neonatal Fc receptor (FcRn) blocker medical

"developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker"

Immunology Innovation Program (IIP) technical

"Partnering with leading academic researchers through its Immunology Innovation Program (IIP)"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership changes did argenx (ARGX) announce in this Form 6-K?

argenx announced that the Board appointed Karen Massey as Chief Executive Officer and named co-founder Tim Van Hauwermeiren as Chairperson of the Board as a non-executive director, marking a leadership transition while maintaining his involvement at board level.

Who is Karen Massey, the new CEO of argenx (ARGX)?

Karen Massey is argenx’s new Chief Executive Officer. She joined argenx in March 2023 as Chief Operating Officer and, according to the Board, has played a central role in shaping execution and long-term growth strategy, emphasizing responsibility to patients, company culture, and pipeline development.

What role will co-founder Tim Van Hauwermeiren hold at argenx (ARGX) now?

Co-founder Tim Van Hauwermeiren, who served as Chief Executive Officer since 2008, has been appointed Chairperson of the Board of Directors as a non-executive director. He will support Karen Massey and the leadership team as argenx enters its next phase of growth.

How much of argenx’s (ARGX) share capital was represented at the Annual General Meeting?

At the Annual General Meeting, 90.9% of argenx’s share capital was represented. This high level of participation indicates broad shareholder engagement in the meeting where leadership changes and other agenda items were presented and voted upon.

Were argenx’s (ARGX) Annual General Meeting proposals approved?

Yes. All items on the Annual General Meeting agenda received the required majority of votes in favor for approval. This includes matters linked to board appointments, such as Karen Massey’s appointment as an executive director and Tim Van Hauwermeiren’s appointment as a non-executive director.

Where can investors find detailed voting results for argenx’s (ARGX) Annual General Meeting?

Detailed voting results and related documents from the Annual General Meeting will be available on the argenx website at www.argenx.com/investors/shareholder-meetings, providing shareholders with access to the full breakdown of resolutions and outcomes.

What does argenx (ARGX) focus on as a company?

argenx is a global immunology company focused on severe autoimmune diseases. It partners with academic researchers through its Immunology Innovation Program and has developed and commercialized the first approved neonatal Fc receptor (FcRn) blocker, while advancing earlier-stage antibody-based medicines across multiple therapeutic franchises.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/06/2026 - 04:28 PM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of May 2026

Commission File Number: 001-38097

ARGENX SE

(Translation of registrant’s name into English)

Laarderhoogtweg 25
1101 EB Amsterdam, the Netherlands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x     Form 40-F  ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

EXPLANATORY NOTE

On May 6, 2026, argenx SE (the “Company”) issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information contained in this Current Report on Form 6-K, including Exhibit 99.1, shall be deemed to be incorporated by reference into the Company’s Registration Statements on Forms S-8 (File Nos. 333-225375, 333-258253, 333-274721, and 333-292200), and to be part thereof from the date on which this Current Report on Form 6-K is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit		Description
99.1		Press Release May 6, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ARGENX SE
Date: May 6, 2026	By:	/s/ Hemamalini (Malini) Moorthy
		Name: Hemamalini (Malini) Moorthy
		Title: General Counsel

Exhibit 99.1

argenx Announces Results of Annual General Meeting and Board of Directors’ Appointment of Karen Massey as Chief Executive Officer

Leadership transition marks next evolution of growth

May 6, 2026

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovator committed to improving the lives of people suffering from severe autoimmune diseases, today announced the results of the Annual General Meeting of shareholders and the Board of Directors’ appointment of Karen Massey as Chief Executive Officer and Tim Van Hauwermeiren as Chairperson of the Board of Directors.

“Karen has earned the full confidence of the Board of Directors and our shareholders,” said Tim Van Hauwermeiren, Chair of the Board of Directors. “She is a proven leader who has played a central role in shaping argenx’s execution and long-term growth strategy. Karen leads with our responsibility to patients, the argenx culture, and a vision to continue to build our pipeline. I look forward to supporting Karen and the leadership team as argenx enters its next phase of growth.”

Karen Massey joined argenx in March 2023 as Chief Operating Officer and will succeed Tim Van Hauwermeiren, who co-founded argenx and has served as Chief Executive Officer since 2008. Her appointment by the Board of Directors as CEO follows shareholder approval of her appointment as executive director of the Board of Directors. The Board of Directors also appointed Tim Van Hauwermeiren as Chairperson of the Board of Directors, effective immediately, following his appointment as non-executive director to the Board of Directors at the General Meeting.

90.9% of the Company’s share capital was represented at the General Meeting.

All items on the agenda received the required majority of votes in favor for approval, including:

· argenx 2025 remuneration report

· argenx annual report and annual accounts for the financial year ending December 31, 2025

· Allocation of the Company’s 2025 profits to the retained earnings

· Karen Massey has been appointed as an executive director to the Board of Directors for a term of 4 years

· Tim Van Hauwermeiren has been appointed as a non-executive director to the Board of Directors for a term of 4 years

· Ana Céspedes has been reappointed as non-executive director to the Board of Directors for a term of 4 years

· Camilla Sylvest has been reappointed as non-executive director to the Board of Directors for a term of 4 years

· Pam Klein has been reappointed as non-executive director to the Board of Directors for a term of 2 years

· Authorization to issue shares and grant rights to subscribe for shares in the share capital of the Company for up to 10% of the outstanding share capital at the date of the meeting and for a period of 18 months from the meeting and to limit or exclude statutory pre-emptive rights

The voting result and all documents relating to the shareholders’ meeting will be available on the argenx

website at www.argenx.com/investors/shareholder-meetings.

 

About argenx

argenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises. For more information, visit www.argenx.com and follow us on LinkedIn, Instagram, Facebook, and YouTube.

For further information, please contact:

Media:

Ben Petok

bpetok@argenx.com

Investors:

Alexandra Roy
aroy@argenx.com

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 EXHIBIT 99.1 13.4 KB